

# Clinical Trial Activity in Ontario Between 2015 – 2023

22

Clinical Trials

9 Completed  
9 Active  
4 Pending

100

Partners

4

Ontario Cities

750+

Patients

Billions  
of Stem Cells!



## BRAIN AND/OR NERVES

**Phase I** using a diabetes drug for brain repair in children with multiple sclerosis: Toronto (Active)

**Phase I** using engineered cell therapy for Parkinson's Disease: Active 2021

**Phase II** using stem cells for multiple sclerosis: Complete

**Phase II** using a diabetes drug for brain repair in children with cerebral palsy: Toronto (Active)

**Phase III** using a diabetes drug to stimulate brain repair for malignant brain tumours: Complete



## GENETIC DISORDERS

**Phase I** using genetically modified stem cells for Fabry disease: Complete



## BLOOD

**Phase I** using cell therapy to help patients recover from radiation/chemotherapies for the treatment of leukemia: Pending 2022–23



## LIVER

**Phase II–III** using stem cells to induce tolerance in recipients of liver transplants: Ottawa and Toronto (Active)



## JOINTS

**Phase I–II** using stem cells for knee osteoarthritis: Complete

**Phase III** using a cartilage tissue implant grown from patient's cells: Complete



## BURNS

**Phase I** using stem cells developed from a patient's surgically removed burned tissue to improve wound healing: Active



## MUSCLE

**Phase I** using a drug to restore muscle regeneration in children with muscular dystrophy: Pending 2022–23



## PAIN

**Phase I** hydrogel-based drug delivery platform for treatment of post-surgical pain: Pending 2021



## HEART

**Phase I** using stem cells to repair heart damage: Pending 2022–23

**Phase II** using genetically modified stem cells following a heart attack: Complete

**Phase II** using stem cells for advanced heart failure with left ventricular assist device: Complete

**Phase II** using cell therapy combined with coronary artery bypass grafting to treat heart failure: Complete



## LUNG

**Phase I** using stem cells for bronchopulmonary dysplasia in pre-term infants: Active

**Phase II** using genetically modified stem cells for pulmonary arterial hypertension: London, Ottawa, Toronto and Hamilton (Active)



## CRITICAL CARE

**Phase I** cell therapy for septic shock: Complete

**Phase II** cell therapy for septic shock: Active 2021

**Phase I** cell therapy for COVID-19 related acute respiratory distress syndrome: Ottawa, Toronto, Montreal (Active)

Five Disease Teams directly funded by OIRM with technologies now in **Phase I/II** trials.

Three Disease Teams directly funded by OIRM with technologies in **Phase I** trials in 1-2 years (2022-23).